PECAM1 and rheumatoid arthritis: Comparing csDMARD-only and TNFi-treated RA patients, a statistically non-significant tendency towards higher proportions of CD31+CD4+ T cells, CD127+CD4+ T cells and TREC containing cells within the TNFi treated group was found (Fig. 2A, C, E).